Table 5.

Main baseline characteristics and clinical outcomes of the 15 patients who developed withdrawal hepatitis^a

Patient no.	Age (yr)	Gender	HBeAg/anti-HBe	HBV DNA at baseline (IU/ml)	Pre-exacerbation HBV DNA nadir (IU/ml)	Liver cirrhosis	Underlying malignancy	HBV DNA at WH (IU/ml)	ALT level at WH (IU/liter)	Duration of LAM after completion of chemotherapy (days)	Time to WH after end of LAM (days)	Rescue therapy	Clinical course
1	58	F	−/+	9.06 × 107	Undetectable	No	Breast cancer	>1.1 × 108	384	103	93	LAM	Improvement
2	57	F	−/+	1.08 × 105	Undetectable	Yes	Breast cancer	2.05 × 105	219	92	74	ETV	Improvement
3	49	F	−/+	Undetectable	Undetectable	No	Breast cancer	2.49 × 107	245	113	174	LAM	Improvement
4	50	M	−/+	3.44 × 104	1,650	No	Colorectal cancer	4.41 × 107	795	166	104	Observation	Improvement
5	39	F	−/+	9.42 × 102	Undetectable	No	Breast cancer	1.58 × 107	107	40	61	LAM	Improvement
6	49	M	−/+	Undetectable	Undetectable	No	NHL	1.41 × 106	1,771	0	177	LAM	Improvement
7	62	M	−/−	2.98 × 105	38	Yes	Colorectal cancer	4.25 × 106	95	54	48	ETV	Improvement
8	60	M	−/+	8.35 × 102	NAb	No	NHL	7.11 × 107	2,762	30	86	ETV	Improvement
9	56	F	−/+	1.20 × 10	Undetectable	No	NHL	3.21 × 106	1,750	72	172	ETV	Improvement
10	59	M	−/−	2.11 × 106	NA	No	NHL	>1.1 × 108	507	96	72	ETV	Improvement
11	59	M	−/+	1.21 × 105	NA	No	Non-small cell lung cancer	>1.1 × 108	323	0	73	LAM	Death due to disease progression
12	60	M	NA	1.23 × 105	240	Yes	Leukemia	2.41 × 105	111	67	152	ETV	Improvement
13	52	M	+/−	1.36 × 106	44	Yes	Stomach cancer	2.67 × 105	118	111	69	Observation	Loss to follow up
14	47	F	−/+	1.74 × 107	51	Yes	Breast cancer	3.00 × 105	48	154	62	Observation	Improvement
15	53	F	NA	NA	NA	Yes	NHL	2.17 × 107	56	0	59	LAM + ADV	Death due to hepatic failure

^aF, female; M, male; ADV, adefovir; anti-HBe, hepatitis B e antibody; ETV, entecavir; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus; LAM, lamivudine; NHL, non-Hodgkin's lymphoma; WH, withdrawal hepatitis.

^bNA, laboratory data were not available at either baseline or nadir.